Part 2 - Coronary angiography with gadofosveset trisodium: a prospective intra-subject comparison for dose optimization for 100 % efficiency imaging
Mark A Ahlman, Fabio S Raman, Jianing Pang, Filip Zemrak, Veit Sandfort, Scott R Penzak, Zhaoyang Fan, Songtao Liu, Debiao Li, David A Bluemke, Mark A Ahlman, Fabio S Raman, Jianing Pang, Filip Zemrak, Veit Sandfort, Scott R Penzak, Zhaoyang Fan, Songtao Liu, Debiao Li, David A Bluemke
Abstract
Background: Three tesla (3T) coronary magnetic resonance angiography (MRA) may be optimized using gadolinium-based contrast agents (GBCA) such as gadofosveset trisodium. The goal of this study was to evaluate if there is a qualitative or quantitative improvement in the coronary arteries with variation in contrast dose.
Methods: Twenty-eight healthy volunteers were prospectively recruited for coronary MRA at 3T using a steady state injection technique for 3D radial whole-heart image acquisition with retrospective respiratory self-gating (ClinicalTrials.gov identifier: NCT01853592). Nineteen volunteers completed both single- and double-dose imaging instances (0.03 and 0.06 mmol/kg, respectively). Intra-individual comparison of image quality was assessed by measurement of apparent signal/contrast-to-noise ratio (aSNR/aCNR) and subjective evaluation of image quality by 2 independent reviewers.
Results: The average duration of coronary MRA acquisition was 7.2 ± 1.2 min. There was significantly higher (60 %, p < 0.001) aSNR of the aorta and right/left ventricle for the double dose compared to single dose injection scheme and aSNR of the coronary arteries increased by 70 % (p < 0.001) for the double dose injection. aCNR increased by +55 % and +60 % in the ventricles and coronary arteries, respectively (p < 0.001). Overall segmental artery visualization for single dose was possible 47 % of the time, which improved to 60 % with double dose (p = 0.019), predominantly driven by improvements in more distal segment visualization (+40 % improvement in mid arterial segments, p = 0.013).
Conclusions: Gadofosveset trisodium dose of 0.06 mmol/kg significantly quantitatively and qualitatively improves the coronary artery image quality compared to 0.03 mmol/kg at 3T for moderate duration (6-8 min) steady state contrast enhanced coronary MRA.
Keywords: 3.0 Tesla; Gadofosveset trisodium; Gadolinium-based intravascular contrast agent; Image quality; MS-325; Navigator-based angiography; Respiratory motion correction; Whole-heart coronary magnetic resonance angiography.
Figures
References
- Gerber TC, Carr JJ, Arai AE, Dixon RL, Ferrari VA, Gomes AS, et al. Ionizing radiation in cardiac imaging. Circulation. 2009;119:1056–65. doi: 10.1161/CIRCULATIONAHA.108.191650.
- Namasivayam S, Kalra MK, Torres WE, Small WC. Adverse reactions to intravenous iodinated contrast media: a primer for radiologists. Emerg Radiol. 2006;12(5):210–5. doi: 10.1007/s10140-006-0488-6.
- Nikolaou K, Alkadhi H, Bamberg F, Leschka S, Wintersperger BJ. MRI and CT in the diagnosis of coronary artery disease: indications and applications. Insights into imaging. 2011;2(1):9–24. doi: 10.1007/s13244-010-0049-0.
- Goyen M, Edelman M, Perreault P, O’Riordan E, Bertoni H, Taylor J, et al. MR angiography of aortoiliac occlusive disease: a phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325. Radiology. 2005;236:825–33. doi: 10.1148/radiol.2363040577.
- Yang Q, Li K, Liu X, Bi X, Liu Z, An J, et al. Contrast-enhanced whole-heart coronary magnetic resonance angiography at 3.0-T: a comparative study with X-ray angiography in a single center. J Am Coll Cardiol. 2009;54(1):69–76. doi: 10.1016/j.jacc.2009.03.016.
- Frydrychowicz A, Russe MF, Bock J, Stalder AF, Bley TA, Harloff A, et al. Comparison of gadofosveset trisodium and gadobenate dimeglumine during time-resolved thoracic MR angiography at 3T. Acad Radiol. 2010;17:1394. doi: 10.1016/j.acra.2010.05.022.
- Perreault P, Edelman MA, Baum RA, Yucel EK, Weisskoff RM, Shamsi K, et al. MR angiography with gadofosveset trisodium for peripheral vascular disease: phase II trial1. Radiology. 2003;229:811–20. doi: 10.1148/radiol.2293021180.
- Hayashi H, Yuasa Y, Amano Y, Tanimoto A, Saito Y, Yoshioka K, et al. Arterial visualization by contrast-enhanced moving-table MR angiography: crossover comparison of 0.1 and 0.2 mmol/kg doses of meglumine gadopentetate in normal volunteers. J Magn Reson Imaging. 2008;28(3):783–90. doi: 10.1002/jmri.21488.
- Heverhagen JT, Wright CL, Schmalbrock P, Knopp MV. Dose comparison of single versus double dose in contrast-enhanced magnetic resonance angiography of the renal arteries: intra-individual cross-over blinded trial using Gd-DTPA. Eur Radiol. 2009;19(1):67–72. doi: 10.1007/s00330-008-1120-9.
- Nacif MS, Arai AE, Lima J, Bluemke DA. Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to United States Food and Drug Administration (FDA) guidelines. J Cardiovasc Magn Reson. 2012;14:18.
- Pang J, Bhat H, Sharif B, Fan Z, Thomson LE, LaBounty T, et al. Whole-heart coronary MRA with 100 % respiratory gating efficiency: Self-navigated three-dimensional retrospective image-based motion correction (TRIM) Magn Reson Med. 2014;71(1):67–74. doi: 10.1002/mrm.24628.
- Pang J, Sharif B, Arsanjani R, Bi X, Fan Z, Yang Q, et al. Accelerated whole-heart coronary MRA using motion-corrected sensitivity encoding with three-dimensional projection reconstruction. Magn Reson Med. 2014.
- Ahlman MA, Raman FS, Penzak SR, Pang J, Li D, Bluemke D. Optimization of gadofosveset intravenous injection scheme for coronary MRA: the pharmacokinetics approach. J Cardiovasc Magn Reson. 2014;16(Suppl 1):160. doi: 10.1186/1532-429X-16-S1-P160.
- Maki JH, Wang M, Wilson GJ, Shutske MG, Leiner T. Highly accelerated first-pass contrast-enhanced magnetic resonance angiography of the peripheral vasculature: comparison of gadofosveset trisodium with gadopentetate dimeglumine contrast agents. J Magn Reson Imaging. 2009;30(5):1085–92. doi: 10.1002/jmri.21961.
- Raman FS, Nacif MS, Cater G, Gai N, Jones J, Li D, et al. 3.0-T whole-heart coronary magnetic resonance angiography: comparison of gadobenate dimeglumine and gadofosveset trisodium. Int J Cardiovasc Imaging. 2013;29(5):1085–94. doi: 10.1007/s10554-013-0192-z.
- Kelle S, Thouet T, Tangcharoen T, Nassenstein K, Chiribiri A, Paetsch I, et al. Whole-heart coronary magnetic resonance angiography with MS-325 (Gadofosveset) Med Sci Monit. 2007;13:CR469–74.
- Prompona M, Cyran C, Nikolaou K, Bauner K, Reiser M, Huber A. Contrast-enhanced whole-heart coronary MRA using Gadofosveset 3.0 T versus 1.5 T. Acad Radiol. 2010;17:862–70. doi: 10.1016/j.acra.2010.02.009.
- Malayeri AA, Macedo R, Li D, Chen S, Bahrami H, Lai S, et al. Coronary vessel wall evaluation by magnetic resonance imaging in the multi-ethnic study of atherosclerosis: determinants of image quality. J Comput Assist Tomogr. 2009;33(1):1. doi: 10.1097/RCT.0b013e3181648606.
- Pang J, Sharif B, Fan Z, Bi X, Arsanjani R, Berman DS, et al. ECG and navigator-free four-dimensional whole-heart coronary MRA for simultaneous visualization of cardiac anatomy and function. Magn Reson Med. 2014;72(5):1208–17. doi: 10.1002/mrm.25450.
- Jahnke C, Paetsch I, Achenbach S, Schnackenburg B, Gebker R, Fleck E, et al. Coronary MR imaging: breath-hold capability and patterns, coronary artery rest periods, and beta-blocker use. Radiology. 2006;239(1):71–8. doi: 10.1148/radiol.2383042019.
- Reiter T, Ritter O, Prince MR, Nordbeck P, Wanner C, Nagel E, et al. Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2012;14:31. doi: 10.1186/1532-429X-14-31.
Source: PubMed